ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Santen Pharma bets on eye implant with US acquisition

OSAKA -- Seeking to make headway into medical hardware, Santen Pharmaceutical will buy a U.S. startup developing an implant for the treatment of glaucoma.

The Japanese drugmaker said Tuesday that it will pay $225 million for privately held InnFocus. A formal agreement is expected in August.

Santen holds the leading share of the Japanese market for prescription eye drugs. Buying InnFocus will could give it a larger presence in medical devices, which now account for only a tiny fraction of its sales.

InnFocus' MicroShunt implant drains fluid from the eye to reduce intraocular pressure. The startup is in late-stage clinical testing in the U.S. and Europe and expects to apply for premarket approval for the device as soon as 2018. The implant could offer a less invasive alternative to conventional glaucoma surgery.

Santen paid some $600 million in 2014 for Merck's ophthalmology drug business in Europe and Asia.

That deal has helped the Japanese company expand in foreign markets, which accounted for 27% of total sales in the year to March 2016. It aims to boost that share to 40-50% by fiscal 2020.

Outside of Japan, Santen takes in just 70 million yen ($660,000) in sales of intraocular lenses and other medical devices. Even when domestic sales are added in, devices contribute only about 2.4 billion yen, or 1%, of annual sales.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media